A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

ClinicalTrials.gov ID: NCT00077649

Public ClinicalTrials.gov record NCT00077649. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Multicenter, Double-blind, Phase IV Pilot Study Evaluating the Effect of PEGASYS Doses of 180 ug or 270 ug in Combination With Copegus Doses of 1200 mg or 1600 mg on Viral Kinetics, Virological Response, Pharmacokinetics, and Safety in Interferon-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Body Weight Greater Than 85 kg

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The effects of treatment with different doses of PEGASYS in combination with different doses of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer, body weight greater than 85kg (187lbs) and no prior treatment with interferon. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

Study identification

NCT ID: NCT00077649
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 188 participants

Conditions and interventions

Conditions

Hepatitis C, Chronic

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2004 (Type not available)
Primary completion: Dec 2005 (Actual)
Completion: Dec 2005 (Actual)
Last update posted: Apr 18, 2016

2004 – 2005

United States locations

U.S. sites: 24
U.S. states: 15
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	La Jolla	California	92037-1030	—
Not listed	Long Beach	California	90822	—
Not listed	San Diego	California	92105	—
Not listed	San Diego	California	92154	—
Not listed	Farmington	Connecticut	06030	—
Not listed	Bradenton	Florida	34209	—
Not listed	Gainesville	Florida	32610-0214	—
Not listed	Jacksonville	Florida	32207	—
Not listed	Wellington	Florida	33414	—
Not listed	Honolulu	Hawaii	96817	—
Not listed	Chicago	Illinois	60612	—
Not listed	Iowa City	Iowa	52242	—
Not listed	Boston	Massachusetts	02111	—
Not listed	St Louis	Missouri	63104	—
Not listed	Manhasset	New York	11030	—
Not listed	Chapel Hill	North Carolina	27599-7584	—
Not listed	Statesville	North Carolina	28677	—
Not listed	Cincinnati	Ohio	45267-0595	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Pittsburgh	Pennsylvania	15213	—
Not listed	Houston	Texas	77030	—
Not listed	Salt Lake City	Utah	84121	—
Not listed	Charlottesville	Virginia	22906-0013	—
Not listed	Richmond	Virginia	23249	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00077649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 18, 2016 · Synced Nov 5, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00077649 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →